Author/Authors :
Wen, Zhili Infectious Disease Hospital of Nanchang University - Department of Hepatology, China , Zhang, Haiming Infectious Disease Hospital of Nanchang University - Department of Hepatology, China , Zhang, Meiying Hospital of Nanchang University - Department of Medicine, China , Tan, Deming Xiangya Hospital of Central South University - Department of Infectious Disease, China , Li, Qinghua People’s Liberation Army Hospital 163 - Department of Medicine, China , Zhang, Hua Infectious Disease Hospital of Nanchang University - Department of Hepatology, China , Wu, Ping Infectious Disease Hospital of Nanchang University - Department of Hepatology, China , Deng, Le Infectious Disease Hospital of Nanchang University - Department of Hepatology, China
Abstract :
Background: Hepatitis B is a common infectious disease in China. Many studies have shown that the genotype of hepatitis B virus (HBV) is probably associated with the efficacy of some antiviral drugs such as interferon α (IFN-α) and Lamivudine (LAM). However, the association between HBV genotype and adefovir dipivoxil (ADV) is controversial. ADV is the most popular antiviral drug in China due to its low price, good antiviral efficacy, few side effects, and convenient of administration.Objectives: This study focused on the effect of HBV genotypes on antiviral efficacy of ADV in patients with chronic hepatitis B infection (CHB). Patients and Methods: A total of 526 HBeAg-positive patients with CHB were randomly allocated into two groups. One group took ADV and another group took placebo. Nested Polymerase Chain Reaction (PCR) with multiple pairs of genotype-specific primers (nPCR-MPP) was used to analyze genotypes of HBV in these patients. Antiviral efficacy after treatment for three, six, 12 months was compared among the patients with different HBV genotypes. Results: Genotype B (73.6%) and genotype C (26.4%) were detected in these patients. After treatment for 12 months, the rate of HBV DNA seroclearance, ALT normalization, and HBeAg seroconversion were significantly higher in ADV group than in placebo group (P 0.05). However, there were no significant differences in these three rates between patients infected with genotype B and C (P 0.05). Conclusions: HBV genotypes B and C have no significant difference in virologic, biochemical, and immunologic response to ADV.
